Sudeep Pharma Limited is a technology-led manufacturer and global supplier of high-quality excipients and specialty ingredients essential to the pharmaceutical, food, and nutrition sectors. The company leverages proprietary, in-house developed process technologies—including encapsulation, spray drying, and liposomal preparations—to drive innovation and product functionality, particularly in enhancing nutrient bioavailability. The business is structured around two key verticals: refined mineral-based single ingredients (such as salts of calcium, iron, and zinc) for core pharmaceutical and food applications, and specialty, application-specific micronutrient systems designed for improved stability and functional performance.

With a history dating back to 1989, Sudeep Pharma has established a significant global footprint, exporting its product portfolio to markets across the United States, Europe, South America, and Asia-Pacific. The company is recognized as a major exporter of mineral ingredients from India and holds key quality certifications. These stringent regulatory approvals, coupled with deep, long-standing relationships with over 1,100 customers globally, underscore its position as a trusted and strategically important partner in the global healthcare ecosystem.

For the year/period ended (Rs. in Cr.)

For year/ period ended ( in Cr.)

(There are no listed peers of the company in India.)

*Market cap @upper band

• Market Position & Product Range: Leading market position with a wide variety of products in a hard-to-enter industry.
• Global Customer Loyalty: Trusted relationships with many customers worldwide, including decades-long partnerships.
• High-Quality Production: Modern, compliant factories in Vadodara and Ireland with large production capacity.
• Innovation and Leadership: Strong research team driving new product success, led by an experienced management.

The Company SUDEEP PHARMA LIMITED IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:

• Capital expenditure towards procurement of machinery for the production line located at Nandesari Facility I (₹ 75.81 Cr.)
• General corporate purposes

At the upper band of IPO ₹ 593, the stock is valued at 53.55 P/E multiple. Hence, well-informed investors subscribe for medium to long term perspective.